Valuation: Bioventix PLC

Market Cap 83.6M 112M 97.59M 89.69M 159M 10.63B 161M 1.08B 419M 5.22B 419M 410M 18B P/E 2026 *
11.9x
P/E 2027 * -
Enterprise Value 78.7M 105M 91.88M 84.44M 149M 10.01B 152M 1.01B 394M 4.92B 395M 386M 16.95B EV / Sales 2026 *
6.3x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
9.38%
Yield 2027 * -
1 week-4.48%
Current month-3.03%
1 month-3.61%
6 months-13.98%
Current year-16.01%
1 week 1,550
Extreme 1550
1,750
1 month 1,500
Extreme 1500
1,850
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,860
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap.
06-23Buy

Chief Financial Officer

534 0.0102%
04-27Buy

Chief Financial Officer

66 0.0013%
04-19Free

Chief Executive Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.48%-41.82%-58.44% 112M
+1.70%+7.41%+3.12%+8.46% 49.15B
+0.92%+3.93%+399.71%+605.33% 40.23B
+1.89%+8.32%+26.06%-6.35% 34.55B
+2.38%+6.35%+21.25%+64.58% 33.09B
+3.96%+10.67%+11.89%+38.86% 25.19B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+133.27% 15.92B
+0.32%+0.58%+13.67%+19.09% 13.83B
+3.30%+0.76%+90.23%+99.12% 13.52B
Average +1.96%+4.56%+66.39%+100.44% 24.26B
Weighted average by Cap. +2.05%+6.10%+91.81%+139.12%

Financials

2026 *2027 *
Net sales 12.5M 16.69M 14.59M 13.41M 23.71M 1.59B 24.07M 161M 62.59M 781M 62.66M 61.31M 2.69B -
Net income 7.11M 9.5M 8.3M 7.63M 13.49M 904M 13.69M 91.6M 35.61M 444M 35.65M 34.88M 1.53B -
Net Debt -4.89M -6.54M -5.71M -5.25M -9.28M -622M -9.42M -63.03M -24.5M -306M -24.53M -24M -1.05B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-07-03 GBX 1,600.00 0.00% 8,810
26-07-02 GBX 1,600.00 -5.88% 16,151
26-07-01 GBX 1,700.00 +3.03% 2,435
26-06-30 GBX 1,650.00 -1.49% 2,755
26-06-29 GBX 1,675.00 0.00% 6,677
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock